Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 10 of 43 for:    FLUORIDE ION AND TRICLOSAN

The Effect of Periodontal Treatment and the Use of Dentifrice on Glycaemic Control in Diabetics

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00763256
Recruitment Status : Completed
First Posted : September 30, 2008
Results First Posted : April 2, 2012
Last Update Posted : July 28, 2015
Sponsor:
Information provided by (Responsible Party):
Colgate Palmolive

Brief Summary:
To test effectiveness of dentifrice in maintaining periodontal health.

Condition or disease Intervention/treatment Phase
Periodontal Disease Drug: Triclosan, Fluoride Drug: Fluoride Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 33 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: The Effect of Periodontal Treatment and the Use of Dentifrice on Glycaemic Control in Diabetics
Study Start Date : May 2006
Actual Primary Completion Date : August 2009
Actual Study Completion Date : August 2009

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Active Comparator: A Drug: Triclosan, Fluoride
subjects brushed their teeth twice daily with the study toothpaste for the assigned treatment period.
Other Name: triclosan/fluoride/copolymer toothpaste

Placebo Comparator: B Drug: Fluoride
subjects brushed their teeth twice daily with the study toothpaste for the assigned study treatment period.
Other Name: current marketed fluoride only toothpaste




Primary Outcome Measures :
  1. HbA1c Levels in Blood [ Time Frame: 12 months ]
    Glycated hemoglobin (HbA1c) is a form of hemoglobin which is measured primarily to identify the average plasma glucose concentration over prolonged periods of time. In this study, blood is taken from each subject and HbA1c levels were measured at 12 months by Queensland Health Pathology Scientific Services (QHPSS).

  2. High Sensitivity CRP (C-Reactive Protein) [ Time Frame: 12 months ]
    CRP is a protein found in the blood and is a marker for inflammation in the body. Inflammation plays a role in the initiation and progression of cardiovascular disease. Blood is taken from each subject and CRP levels were measured at 12 months by Queensland Health Pathology Scientific Services (QHPSS).

  3. C-Peptide [ Time Frame: 12 months ]
    C-Peptide levels in blood indicate whether or not a person is producing insulin. This peptide is usually found in equal levels to insulin. C-peptide levels measured as a means of distinguishing type 1 diabetes and type 2 diabetes. Blood is taken from each subject and C-Peptide levels were measured at 12 months by Queensland Health Pathology Scientific Services (QHPSS).

  4. Gingivitis Score (GI) [ Time Frame: 12 months ]

    Units on a scale 0 to 3 (0 = no inflammation,

    1 = Mild inflammation-slight change in color and little change in texture 2 = Moderate inflammation-moderate glazing, redness, edema and hypertrophy. Tendency to bleed upon probing. 3 = Severe inflammation-marked redness and hypertrophy. Tendency to spontaneous bleeding)


  5. P. Gingivalis [ Time Frame: 12 months ]
    Subgingival plaque samples were collected from all interproximal (mesial) sites and pooled prior to assessment. The samples will be analysed for the presence of P. gingivalis, using real time PCR to quantitate the numbers of bacteria. P. gingivalis is a non-motile, gram negative, anaerobic, pathogenic bacteria. It is linked to periodontal disease and causes collagen degradation.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Poor glycaemic control as evidenced by an HbA1c of >6.0% for the past 12 months
  • Aged 18 to 75 years
  • Able to give informed consent
  • Minimum of 12 teeth
  • Chronic periodontitis as indicated by periodontal probing depths >5mm on at least 6 teeth

Exclusion Criteria:

  • Pregnancy
  • Gross dental caries
  • Prosthetic heart valves, a history of infective endocarditis or any other condition requiring antibiotic cover for dental treatment (rheumatic fever, mitral valve prolapse with regurgitation)
  • Anticoagulant therapy (excluding asprin)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00763256


Locations
Layout table for location information
Australia
Logan Hospital Oral Health Clinic
Queensland, Australia
Sponsors and Collaborators
Colgate Palmolive
Investigators
Layout table for investigator information
Principal Investigator: Gregory Seymour, BDS University of Otago

Layout table for additonal information
Responsible Party: Colgate Palmolive
ClinicalTrials.gov Identifier: NCT00763256     History of Changes
Other Study ID Numbers: 2004000841/2004/201
First Posted: September 30, 2008    Key Record Dates
Results First Posted: April 2, 2012
Last Update Posted: July 28, 2015
Last Verified: July 2015
Additional relevant MeSH terms:
Layout table for MeSH terms
Triclosan
Fluorides
Periodontal Diseases
Mouth Diseases
Stomatognathic Diseases
Cariostatic Agents
Protective Agents
Physiological Effects of Drugs
Anti-Infective Agents, Local
Anti-Infective Agents
Fatty Acid Synthesis Inhibitors
Hypolipidemic Agents
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Lipid Regulating Agents